Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Mar 19, 2020 9:06pm
54 Views
Post# 30828820

RE:RE:RE:The plant checkpoints are obviously done:

RE:RE:RE:The plant checkpoints are obviously done:

Hey DryBones, so you're saying that they are lying on the MD&A? You've been here a long time. Have you challenged management with your accusations? What have they said? It's clear that they seem to be cleanly through those process controls. Are you just 100% speculating or do you have some theory or evidence to share? 

DryBones wrote: Nothing more can be expected of LMNL until management finally concedes and admits that the checkpoint quality control issue cannot be solved.  The purification process must be written off as a technologicial failure.  To get Ryplazim and the clinical trials approved by the FDA will require purchase from other sources.  Then they must license that methodology,  the cone process.

This business of proping up the stock with buys way over the ask will not save Thomies big investment.

The Tomies should give up their nasty deception and let the SP find its value,  which is less than a buck.

AS for the rest of us,  we are all losers, learn to live with it.  

 

<< Previous
Bullboard Posts
Next >>